File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, α-galactosylceramide

TitleEnhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, α-galactosylceramide
Authors
Issue Date2008
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
Citation
Vaccine, 2008, v. 26 n. 15, p. 1807-1816 How to Cite?
AbstractA number of studies have shown that the natural killer T cell (NKT) ligand α-galactosylceramide (α-GalCer) serves as an adjuvant for various vaccines, including viral vaccines, parasite vaccines and protein vaccines. In this report, we investigated the adjuvant activity of α-GalCer on HIV-1 DNA vaccines in mice. This is a first study to show that α-GalCer can enhance the immunogenicity of DNA vaccines, since co-administration of α-GalCer with suboptimal doses of DNA vaccines greatly enhanced antigen-specific CD4+ T-cell and CD8+ T-cell responses. Differently from other vaccines, α-GalCer was also able to enhance HIV-specific antibody response 10-fold. It is of practical importance to find out that, in a DNA prime-DNA boost regimen, the adjuvant activity of α-GalCer was most profound when co-administered at the priming, but not at the boosting phase. In a dose-sparing experiment, we found that the level of cell-mediated immune responses in mice vaccinated with 5 μg of DNA in the presence of α-GalCer was equivalent to that of mice vaccinated with 50 μg of DNA in the absence of α-GalCer. Finally, results from CD1d and interferon-γ receptor knockout mice confirm our previous data and determine the mechanistic dependence upon these molecules. These results illustrate that α-GalCer enhances the immunogenicity of DNA vaccines in a mechanism-based fashion. Since both mice and humans share the CD1d molecule, this information may aid in designing more effective DNA vaccines and vaccine adjuvants against HIV-1. © 2008 Elsevier Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/157510
ISSN
2015 Impact Factor: 3.413
2015 SCImago Journal Rankings: 2.044
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorHuang, Yen_US
dc.contributor.authorChen, Aen_US
dc.contributor.authorLi, Xen_US
dc.contributor.authorChen, Zen_US
dc.contributor.authorZhang, Wen_US
dc.contributor.authorSong, Yen_US
dc.contributor.authorGurner, Den_US
dc.contributor.authorGardiner, Den_US
dc.contributor.authorBasu, Sen_US
dc.contributor.authorHo, DDen_US
dc.contributor.authorTsuji, Men_US
dc.date.accessioned2012-08-08T08:50:43Z-
dc.date.available2012-08-08T08:50:43Z-
dc.date.issued2008en_US
dc.identifier.citationVaccine, 2008, v. 26 n. 15, p. 1807-1816en_US
dc.identifier.issn0264-410Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/157510-
dc.description.abstractA number of studies have shown that the natural killer T cell (NKT) ligand α-galactosylceramide (α-GalCer) serves as an adjuvant for various vaccines, including viral vaccines, parasite vaccines and protein vaccines. In this report, we investigated the adjuvant activity of α-GalCer on HIV-1 DNA vaccines in mice. This is a first study to show that α-GalCer can enhance the immunogenicity of DNA vaccines, since co-administration of α-GalCer with suboptimal doses of DNA vaccines greatly enhanced antigen-specific CD4+ T-cell and CD8+ T-cell responses. Differently from other vaccines, α-GalCer was also able to enhance HIV-specific antibody response 10-fold. It is of practical importance to find out that, in a DNA prime-DNA boost regimen, the adjuvant activity of α-GalCer was most profound when co-administered at the priming, but not at the boosting phase. In a dose-sparing experiment, we found that the level of cell-mediated immune responses in mice vaccinated with 5 μg of DNA in the presence of α-GalCer was equivalent to that of mice vaccinated with 50 μg of DNA in the absence of α-GalCer. Finally, results from CD1d and interferon-γ receptor knockout mice confirm our previous data and determine the mechanistic dependence upon these molecules. These results illustrate that α-GalCer enhances the immunogenicity of DNA vaccines in a mechanism-based fashion. Since both mice and humans share the CD1d molecule, this information may aid in designing more effective DNA vaccines and vaccine adjuvants against HIV-1. © 2008 Elsevier Ltd. All rights reserved.en_US
dc.languageengen_US
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccineen_US
dc.relation.ispartofVaccineen_US
dc.rightsVaccine. Copyright © Elsevier Ltd.-
dc.subject.meshAids Vaccines - Immunologyen_US
dc.subject.meshAdjuvants, Immunologic - Administration & Dosageen_US
dc.subject.meshAnimalsen_US
dc.subject.meshAntibodies, Viral - Blooden_US
dc.subject.meshAntigens, Cd1 - Geneticsen_US
dc.subject.meshAntigens, Cd1den_US
dc.subject.meshCd4-Positive T-Lymphocytes - Immunologyen_US
dc.subject.meshCd8-Positive T-Lymphocytes - Immunologyen_US
dc.subject.meshFemaleen_US
dc.subject.meshGalactosylceramides - Administration & Dosageen_US
dc.subject.meshHiv Infections - Prevention & Controlen_US
dc.subject.meshHiv-1 - Genetics - Immunologyen_US
dc.subject.meshImmunization, Secondary - Methodsen_US
dc.subject.meshMiceen_US
dc.subject.meshMice, Inbred Balb Cen_US
dc.subject.meshMice, Knockouten_US
dc.subject.meshReceptors, Interferon - Deficiencyen_US
dc.subject.meshVaccines, Dna - Immunologyen_US
dc.titleEnhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, α-galactosylceramideen_US
dc.typeArticleen_US
dc.identifier.emailChen, Z:zchenai@hkucc.hku.hken_US
dc.identifier.authorityChen, Z=rp00243en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.vaccine.2008.02.002en_US
dc.identifier.pmid18329757-
dc.identifier.scopuseid_2-s2.0-40849106237en_US
dc.identifier.hkuros147738-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-40849106237&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume26en_US
dc.identifier.issue15en_US
dc.identifier.spage1807en_US
dc.identifier.epage1816en_US
dc.identifier.isiWOS:000255326700002-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridHuang, Y=7501575029en_US
dc.identifier.scopusauthoridChen, A=15122218600en_US
dc.identifier.scopusauthoridLi, X=36149840800en_US
dc.identifier.scopusauthoridChen, Z=35271180800en_US
dc.identifier.scopusauthoridZhang, W=7409430773en_US
dc.identifier.scopusauthoridSong, Y=10141178900en_US
dc.identifier.scopusauthoridGurner, D=23491754700en_US
dc.identifier.scopusauthoridGardiner, D=7101800882en_US
dc.identifier.scopusauthoridBasu, S=9943541500en_US
dc.identifier.scopusauthoridHo, DD=7402971998en_US
dc.identifier.scopusauthoridTsuji, M=7402169800en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats